157 related articles for article (PubMed ID: 16806435)
1. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
[TBL] [Abstract][Full Text] [Related]
2. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
4. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC
Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
6. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
[TBL] [Abstract][Full Text] [Related]
7. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells.
Suzuki N; Aoki D; Tamada Y; Susumu N; Orikawa K; Tsukazaki K; Sakayori M; Suzuki A; Fukuchi T; Mukai M; Kojima-Aikawa K; Ishida I; Nozawa S
Gynecol Oncol; 2004 Nov; 95(2):290-8. PubMed ID: 15491748
[TBL] [Abstract][Full Text] [Related]
8. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
9. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
12. Antibody-IL-2 fusion proteins: a novel strategy for immune protection.
Penichet ML; Harvill ET; Morrison SL
Hum Antibodies; 1997; 8(3):106-18. PubMed ID: 9322080
[TBL] [Abstract][Full Text] [Related]
13. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
Figini M; Martin F; Ferri R; Luison E; Ripamonti E; Zacchetti A; Mortarino M; Di Cioccio V; Maurizi G; Allegretti M; Canevari S
Cancer Immunol Immunother; 2009 Apr; 58(4):531-46. PubMed ID: 18704410
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
16. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
[TBL] [Abstract][Full Text] [Related]
17. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
18. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
19. Photoimmunotherapy of human ovarian carcinoma cells ex vivo.
Goff BA; Bamberg M; Hasan T
Cancer Res; 1991 Sep; 51(18):4762-7. PubMed ID: 1716512
[TBL] [Abstract][Full Text] [Related]
20. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
